All In Biotech

BLA 761261 · Genzyme Corp

Xenpozyme

Olipudase Alfa-Rpcp · Injection

NovelBreakthrough therapyPriority reviewOrphan

CDER novel approval, Aug 31, 2022: To treat Acid Sphingomyelinase Deficiency

Last checked: Nov 20, 2026Latest source record: Dec 20, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2022

Aug 31, 2022

Approved uses

1

Original approval plus efficacy supplements

Registered trials

4

1 Phase 3, 1 recruiting

FAERS reports

137

32 serious, 2 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS Patients treated with XENPOZYME have experienced life-threatening hypersensitivity reactions, including anaphylaxis. Appropriate medical monitoring and support measures, including cardiopulmonary resuscitation equipment, should be readily available during XENPOZYME administration. If a severe hypersensitivity reaction (e.g., anaphylaxis) occurs, discontinue XENPOZYME immediately and initiate appropriate medical treatment. In patients with severe hypersensitivity reactions, a desensitization procedure to XENPOZYME may be considered [see Warnings and Precautions (5.1) ] . WARNING: HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS See full prescribing information for complete boxed warning. Appropriate medical monitoring and support measures, including cardiopulmonary resuscitation equipment, should be readily available. If a severe...

What it is approved for

From the label in effect Dec 11, 2025.

XENPOZYME is indicated for treatment of non–central nervous system manifestations of acid sphingomyelinase deficiency (ASMD) in adult and pediatric patients. XENPOZYME is a hydrolytic lysosomal sphingomyelin-specific enzyme indicated for treatment of non–central nervous system manifestations of acid sphingomyelinase deficiency (ASMD) in adult and pediatric patients. ( 1 )

Mechanism: ASMD is a lysosomal storage disease that results from reduced activity of the enzyme acid sphingomyelinase (ASM), caused by pathogenic variants in the sphingomyelin phosphodiesterase 1 gene. ASM degrades sphingomyelin to ceramide and phosphocholine. The deficiency of ASM causes an intra-lysosomal accumulation of sphingomyelin (as well as cholesterol and other cell membrane lipids) in various tissues. XENPOZYME provides an exogenous source of ASM. XENPOZYME is not expected to cross the blood-brain barrier or modulate the CNS manifestations of ASMD.

Therapeutic areas: Rare and genetic disease

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 31, 2022 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLetterLabelReview
1 products under this application
  • XENPOZYME · OLIPUDASE ALFA-RPCP 20MG · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Olipudase Alfa" as an intervention, any sponsor and status, largest first.

All 4 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • headache10
  • incorrect dose administered10
  • weight increased10
  • fatigue9
  • nausea7
  • off label use6
  • vomiting6
  • aspartate aminotransferase increased5
  • condition aggravated5
  • erythema5
  • illness5
  • pyrexia5

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20223
202339
202435
202529
202631

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

  • Current · updated Nov 19, 2026

    Xenpozyme, Injection, 20 mg/5.1 mL (NDC 58468-0050-1). Supply concerns for late November through early December 2026; See the following site for additional information from Sanofi:...

  • Current · updated Nov 19, 2026

    Xenpozyme, Injection, 4 mg/1.1 mL (NDC 58468-0051-1). Supply concerns for late November through early December 2026; See the following site for additional information from Sanofi:...

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Xenpozyme (Olipudase Alfa-Rpcp)

2024 spending

$6.6M

Beneficiaries

n/a

50 claims

Per beneficiary

n/a

$6,080.89 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$5,083,777
2024$6,644,633

Part B: Xenpozyme (Olipudase Alfa-Rpcp) · HCPCS J0218

2024 spending

$1.3M

Beneficiaries

n/a

18 claims

Per beneficiary

n/a

2024 ASP limit $379.48 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$1,345,196

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 9 on PubMed

Sponsor: Sanofi

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.